Program
Caffeine
Also written as “caffeine”, “ibuprofen + caffeine” and “Paracetamol and Caffeine”.
Its studies are mostly in Pain · Neoplasms · Pain, Postoperative · Common Cold · Obesity, led by 6 companies.
Drug pageCaffeine: every studyMany companies study it; this page follows only the 16 they lead. All 247 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 60 open or running | phase 3since Aug 22, 2013 | Jun 13, 2013 | none ahead |
| GlaxoSmithKlineits history only | 50 open or running | phase 4since Nov 3, 2011 | Mar 1, 2007 | none ahead |
| Pfizerits history only | 20 open or running | phase 3since Aug 8, 2016 | Aug 8, 2016 | none ahead |
| Hypera Pharmaits history only | 10 open or running | phase 3since Jul 28, 2010 | Jul 28, 2010 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Mar 1, 2007.
- Nov 23, 2010Novartis’s first study: phase 4 study in PainNew to NovartisNovartis · NCT01248468 · 752 enrolled · United States
- Aug 31, 2011Sanofi’s first study: phase 3 study in PainNew to SanofiSanofi · NCT01426971
- Nov 3, 2011Phase 4 study in Common ColdGlaxoSmithKline · NCT01466348 · 72 enrolled · United Kingdom
- Sep 13, 2012Phase 3 study in Common ColdGlaxoSmithKline · NCT01686646 · 240 enrolled · United Kingdom
- Apr 25, 2013Phase 3 study in PainGlaxoSmithKline · NCT01842633 · 365 enrolled · United States
- Jun 13, 2013Boehringer Ingelheim’s first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT01879371 · 36 enrolled · Germany
- Aug 22, 2013Phase 3 study in Pain, PostoperativeBoehringer Ingelheim · NCT01929031 · 562 enrolled · United States
- Jul 7, 2014Phase 3 study in Migraine DisordersBoehringer Ingelheim · NCT02183688 · 1,889 enrolled
- Dec 10, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02629354 · 36 enrolled · South Africa
- Aug 8, 2016Pfizer’s first study: phase 3 study in PainNew to PfizerPfizer · NCT02863575 · 374 enrolled · United States
- Sep 19, 2016Phase 4 study in PainGlaxoSmithKline · NCT02974114 · 21 enrolled · United Kingdom
- Nov 17, 2016Phase 3 study in Back PainBoehringer Ingelheim · NCT03003000 · 635 enrolled · Germany, Russian Federation
- Dec 3, 2020Phase 1 study in Healthy ParticipantsPfizer · NCT04655040 · 12 enrolled · United States
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany
TargetBeta
“Adenosine receptor antagonist; Adenosine receptor antagonist”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05741385Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Aug 9, 2024 | 4 |
| NCT04655040Healthy Participants · United States | 1 | Completed | Pfizer | Mar 5, 2021 | 12 |
| NCT03003000Back Pain · Germany, Russian Federation | 3 | Completed | Boehringer Ingelheim | Sep 24, 2017 | 635 |
| NCT02974114Pain · United Kingdom | 4 | Terminated | GlaxoSmithKline | Feb 6, 2017 | 21 |
| NCT02863575Pain · United States | 3 | Completed | Pfizer | Apr 6, 2018 | 374 |
| NCT02629354Healthy · South Africa | 1 | Completed | Boehringer Ingelheim | Jan 2016 | 36 |
| NCT02183688Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jan 2003 | 1,889 |
| NCT01929031Pain, Postoperative · United States | 3 | Completed | Boehringer Ingelheim | Mar 2014 | 562 |
| NCT01879371Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2013 | 36 |
| NCT01842633Pain · United States | 3 | Terminated | GlaxoSmithKline | Mar 31, 2015 | 365 |
| NCT01686646Common Cold · United Kingdom | 3 | Completed | GlaxoSmithKline | Nov 2012 | 240 |
| NCT01466348Common Cold · United Kingdom | 4 | Completed | GlaxoSmithKline | Apr 2011 | 72 |
| NCT01426971Pain | 3 | Withdrawn | Sanofi | Jun 2013 | 0 |
| NCT01248468Pain · United States | 4 | Completed | Novartis | Mar 2011 | 752 |
| NCT01172405Headache | 3 | UNKNOWN | Hypera Pharma | Oct 2012 | 144 |
| NCT00443170Anemia · Australia | 1 | Completed | GlaxoSmithKline | 90 |
How it is read
Names in the registry
- “Caffeine”, 11 entries
- “caffeine”, 4 entries
- “ibuprofen + caffeine”, 3 entries
- “Paracetamol and Caffeine”, 2 entries
- “Cocktail (Warfarin/Caffeine/Midazolam)”, 1 entry
Conditions, from the studies’ own filings
- Pain, 5 studies
- Neoplasms, 2 studies
- Pain, Postoperative, 2 studies
- Common Cold, 2 studies
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.